Epigenetics
Epigenetics is typically defined as the study of heritable changes in gene expression that are not due to changes in DNA sequence. Epigenetic modifications of chromatin have been shown to play a major role in cancer onset and development. Acetylation and methylation are the most-studied chromatin marks, having fundamental functions in the epigenetic regulation of gene expression[1],[2].
Epigenetic modification of histones is a reversible process. Histone acetyltransferases (HATs) are the enzymes responsible for the introduction of acetyl groups on histones, whereas methyl groups can be introduced both on DNA and histones by DNA methyltransferases (DNMTs) and histone methyltransferases (HMTs)[3]. The removal of methyl and acetyl groups is enzymatically mediated by the action of histone demethylases (HDMs) and histone deacetylases (HDACs), respectively. In turn, epigenetic marks can be recognized by and bound to specific protein domains, such as bromodomain and malignant brain tumor (MBT). These complexes are important intermediates in the epigenetic regulation of gene expression[4].
Axon Medchem offers a wide selection of bioactive small molecules to modulate epigenetic mechanisms, serving researchers in their objective to investigate biological consequences of chromatin modifications and develop new drugs for cancer treatment.
Epigenetic products Library
For your convenience, you can order a library of all of our Epigenetics related products. Make your personal library by cherry picking products of your interest from our comprehensive list (125 products), or order all together not to miss any. The libraries will be shipped as 10 mM solutions (in DMSO, 250 µL of each selected Axon Ligand™) on a 96-well microtiter plate with a clear map of its contents.
Simply download our comprehensive list of epigenetics products below (Microsoft Excel (.xls)), check the products to be included, and return your list to order the library of your preference.
 Axon Ligands™ - Epigenetics Library.xls |
Modifiers of Histone
|
Histone Demethylase (LSD/Jumonji C) |
Histone Deacetylase (HDAC) |
|
SET domain lysine Methyltransferase (G9a/EZH2) |
Histone Deacetylase (SIRT) |
|
Arginine Methyltransferase (PRMT) |
|
|
DNA Methyltransferase (DNMT) |
|
Recognition of modified Histone
|
Recognition of Acetylated Lysine (Bromodomains) |
Recognition of Metylated Lysine (Kme/MBT) |
[1] Epigenetics in Cancer. Manel Esteller.N Engl J Med 2008; 358, 1148-1159.
[2] Epigenetic protein families: a new frontier for drug discovery. CH Arrowsmith et al. Nature 2012, 11, 384-400.
[3] Histone acetyltransferases as emerging drug targets. FJ Dekker and HJ Haisma. Drug Discov. Today 2009, 14(19-20), 942-948.
[4] Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family. Filippakopoulos, P. et al. Cell 2012, 149, 214-231
.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 1378 | AG 490 | JAK2 inhibitor | €65.00 | |
| 1778 | AZ 960 | JAK2 inhibitor | €95.00 | |
| 1955 | Baricitinib | Inhibitor of JAK1 and JAK2 | €70.00 | |
| 1338 | CP 690550 | JAK3 inhibitor | €60.00 | |
| 3861 | Decernotinib | Potent and selective,orally bioavailable Janus kinase 3 (JAK3) inhibitor | Inquire | |
| 4006 | GLPG-0634 | The first orally-available, selective inhibitor of JAK1 | Inquire | |
| 1843 | JAK2 inhibitor 13 | JAK2 inhibitor | €110.00 | |
| 2554 | LY 2784544 | Potent, selective and ATP-competitive inhibitor of mutated janus kinase 2 (JAK2V617F) | €95.00 | |
| 1681 | Momelotinib | JAK1 and JAK2 inhibitor | €80.00 | |
| 4124 | Momelotinib hydrochloride | JAK1 and JAK2 inhibitor | €120.00 | |
| 2792 | NVP-BSK805 | Potent, selective and orally bioavailable JAK2 inhibitor | €125.00 | |
| 2217 | PF 956980 | JAK3 inhibitor; analogue of Axon 1338 and 2072 | €90.00 | |
| 1598 | Ruxolitinib | JAK1 and JAK2 inhibitor | €65.00 | |
| 2539 | Solcitinib | Selective JAK1 inhibitor for treatment of degenerative and inflammatory diseases | €90.00 | |
| 1588 | TG 101348 | JAK2 inhibitor | €80.00 | |
| 2072 | Tofacitinib citrate | Potent Janus Kinase 3 (JAK3) inhibitor | €115.00 | |
| 2231 | XL 019 | JAK2 inhibitor | €100.00 | |